Who are Rhythm Pharmaceuticals's investors?

Rhythm Pharmaceuticals's investors include Foresite Capital, HEALTHCARE ROYALTY PARTNERS, New Enterprise Associates (NEA), Pfizer Venture Investments, OrbiMed, Third Rock Ventures.

How much funding has Rhythm Pharmaceuticals raised?

Rhythm Pharmaceuticals has disclosed $60.5M raised across 2 rounds.

Where is Rhythm Pharmaceuticals headquartered?

Rhythm Pharmaceuticals is headquartered in Boston, US.

Rhythm Pharmaceuticals

Boston, US · Founded 2013 · 494 employees on LinkedIn · 6 known investors

Find your way into Rhythm Pharmaceuticals

257 people in our graph share verified history with the Rhythm Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.

Elizabeth Stonerunlockedknows Bart Henderson · together at Rhythm Pharmaceuticals (overlapped)

knows the team · via Rhythm Pharmaceuticals

×10knows the team · via Flagship Pioneering

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway. The company's lead product, IMCIVREE (setmelanotide), is FDA-approved to treat severe obesity caused by genetic impairments in the hypothalamus.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Keith GottesdienerPresident and Chief Executive Officer2011–2020Investor at Prime Medicine, Inc.

Bart Henderson President and Founder2008–2017Bart Henderson founded Rhythm Pharmaceuticals and co-founded Torque (later Repertoire); he was a founding employee at Radius, where he contributed to the development of multiple FDA-approved medicines including treatments for osteoporosis and metastatic breast cancer.

David MeekerPresident and Chief Executive OfficerPRESIDENT AND CHIEF EXECUTIVE OFFICER at KSQ Therapeutics

Board

Edward T. Mathers Board directorPartner at New Enterprise Associates (NEA)

Jonathan Silverstein Board directorPartner at OrbiMed

Neil Exter Board directorRetired Partner at Third Rock Ventures

Todd FoleyBoard director

Christophe JeanBoard director

David J. McGirrBoard director

David P. Meeker, M.D.Board director

Investors · 6

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · Not right? Tell us

HEALTHCARE ROYALTY PARTNERSlisted by HEALTHCARE ROYALTY PARTNERSNew York

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

How we know: board seat on SEC Form D · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us

OrbiMedinferredNew York · $1M – $75Mvia Jonathan Silverstein · board

How we know: board seat on SEC Form D · Not right? Tell us

Third Rock VenturesinferredBoston · $100K – $5Mvia Neil Exter · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$60.5M disclosed across 2 rounds · 2015–2017

▶$20.5MraisedJan 2017 · 14 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

David P. Meeker, M.D.Director
Neil ExterDirector
David J. McGirrDirector
Jonathan SilversteinDirector
Edward T. MathersDirector
Christophe JeanDirector
Bart HendersonExecutive Officer, Promoter
Todd FoleyDirector
Keith GottesdienerExecutive Officer, Director, Promoter

Offering amount: $40.9M
Amount sold: $20.5M
First sale: Jan 2017
Incorporated: Corporation, Delaware, 2013
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$40MraisedDec 2015 · 12 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Edward T. MathersDirector
David J. McGirrDirector
Jonathan SilversteinDirector
Keith GottesdienerExecutive Officer, Director
David P. Meeker, M.D.Director
Neil ExterDirector
Bart HendersonExecutive Officer
Todd FoleyDirector
Christophe JeanDirector

Offering amount: $40M
Amount sold: $40M
First sale: Aug 2015
Incorporated: Corporation, Delaware, 2013
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

4 people who came through Rhythm Pharmaceuticals went on to found or lead other companies.

Andrew GottesdienerSummer InternFounded Apogee Therapeutics +1 Elizabeth StonerSenior Clinical AdvisorFounded Semma Therapeutics Bart HendersonMr. Henderson is the President and Treasurer of the Issuer.Founded Wavebreaktx Jennifer GoodBoard MemberFounded Trevi Therapeutics

Frequently asked questions

What does Rhythm Pharmaceuticals do?: Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway. The company's lead product, IMCIVREE (setmelanotide), is FDA-approved to treat severe obesity caused by genetic impairments in the hypothalamus.
Who are Rhythm Pharmaceuticals's investors?: Rhythm Pharmaceuticals's investors include Foresite Capital, HEALTHCARE ROYALTY PARTNERS, New Enterprise Associates (NEA), Pfizer Venture Investments, OrbiMed, Third Rock Ventures.
How much funding has Rhythm Pharmaceuticals raised?: Rhythm Pharmaceuticals has disclosed $60.5M raised across 2 rounds.
Where is Rhythm Pharmaceuticals headquartered?: Rhythm Pharmaceuticals is headquartered in Boston, US.